clofazimine has been researched along with Buruli Ulcer Disease in 5 studies
Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619)
clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment of Buruli ulcer, or Mycobacterium ulcerans disease, has shifted from surgical excision and skin grafting to antibiotic therapy usually with 8 weeks of daily rifampin (RIF) and streptomycin (STR)." | 3.81 | Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans Disease. ( Adamson, J; Converse, PJ; Grosset, JH; Kishi, Y; Li, SY; Nuermberger, EL; Tyagi, S; Xing, Y, 2015) |
| "Buruli ulcer is a necrotizing cutaneous infection caused by infection with Mycobacterium ulcerans bacteria that occurs mainly in tropical and subtropical regions." | 2.58 | Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease). ( Ishii, N; Richardson, M; Yotsu, RR, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Converse, PJ | 3 |
| Almeida, DV | 2 |
| Tasneen, R | 1 |
| Saini, V | 1 |
| Tyagi, S | 3 |
| Ammerman, NC | 1 |
| Li, SY | 2 |
| Anders, NM | 1 |
| Rudek, MA | 1 |
| Grosset, JH | 2 |
| Nuermberger, EL | 3 |
| Yotsu, RR | 1 |
| Richardson, M | 1 |
| Ishii, N | 1 |
| Xu, J | 1 |
| Xing, Y | 1 |
| Kishi, Y | 1 |
| Adamson, J | 1 |
| Nenoff, P | 1 |
| Uhlemann, R | 1 |
| Grünewald, T | 1 |
| Nenning, H | 1 |
| Grunewald, S | 1 |
| Paasch, U | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis[NCT03474198] | Phase 2/Phase 3 | 675 participants (Actual) | Interventional | 2018-03-21 | Completed | ||
| Randomized Controlled Trial Comparing Efficacy of 8 Weeks Treatment With Clarithromycin and Rifampicin Versus Streptomycin and Rifampicin for Buruli Ulcer (M. Ulcerans Infection)[NCT01659437] | Phase 2/Phase 3 | 310 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for clofazimine and Buruli Ulcer Disease
| Article | Year |
|---|---|
Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease).
Topics: Anti-Bacterial Agents; Buruli Ulcer; Clarithromycin; Clofazimine; Drug Therapy, Combination; Humans; | 2018 |
4 other studies available for clofazimine and Buruli Ulcer Disease
| Article | Year |
|---|---|
Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer.
Topics: Animals; Anti-Bacterial Agents; Buruli Ulcer; Clofazimine; Dose-Response Relationship, Drug; Drug Ad | 2018 |
Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer.
Topics: Animals; Anti-Bacterial Agents; Buruli Ulcer; Clofazimine; Dose-Response Relationship, Drug; Drug Ad | 2018 |
Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer.
Topics: Animals; Anti-Bacterial Agents; Buruli Ulcer; Clofazimine; Dose-Response Relationship, Drug; Drug Ad | 2018 |
Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer.
Topics: Animals; Anti-Bacterial Agents; Buruli Ulcer; Clofazimine; Dose-Response Relationship, Drug; Drug Ad | 2018 |
Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Buruli Ulcer; Clarithromycin; Clofazimine; Disease M | 2019 |
Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans Disease.
Topics: Animals; Buruli Ulcer; Clarithromycin; Clofazimine; Colony Count, Microbial; Drug Evaluation, Precli | 2015 |
[Atypical mycobacteriosis of the skin caused by Mycobacterium abscessus in an immunocompetent woman].
Topics: Antitubercular Agents; Biopsy; Buruli Ulcer; Clofazimine; Drug Therapy, Combination; Female; Follow- | 2007 |